Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

23 May 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 4519.T


CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as... (more)


Sell Hold Buy
2.38 Mean rating from 13 analysts


Beta: 0.64
Market Cap(Mil.): ¥2,650,113.00
Shares Outstanding(Mil.): 559.69
Dividend: 29.00
Yield (%): 1.16

BRIEF-Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit

* Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd

Nikkei rallies as markets hope China and U.S. will avoid full-blown trade war

TOKYO, April 5 Japanese stocks rose on Thursday morning after Wall Street bounced back from a sell-off triggered by an escalating U.S.-China trade spat.

UPDATE 2-Pfizer's biosimilar of Roche's Rituxan succeeds in study

Jan 24 Pfizer Inc said on Wednesday its biosimilar of Roche's Rituxan was as effective as the original drug in treating patients with a type of follicular lymphoma, meeting the main goal of a study.

Swiss stocks - Factors to watch on Jan 19

ZURICH, Jan 19 The Swiss blue-chip SMI was seen opening 0.13 percent lower at 9,440 points on Friday, according to premarket indications by bank Julius Baer .

BRIEF-CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order

* Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd

BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei‍​

* CHUGAI PHARMACEUTICAL LOOKS TO INVEST SOME 25 BILLION YEN INTO A SINGAPORE RESEARCH CENTER FOR BIOPHARMACEUTICALS BY 2021 - NIKKEI‍​ Source text :(s.nikkei.com/2CitZyn) Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-Chiome Bioscience says termination of joint research contract

* Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD, as the contract has expired on Dec. 31

BRIEF-Chugai Pharmaceutical says change of chief executive officer

* Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018


  • U.S.
  • Europa
  • Asien
  • Branchen


Energie -1.01%
Rohstoffe -0.41%
Industrie -0.14%
Konjunktur abhängige Waren & Dienstleistungen +0.32%
Konjunktur unabhängige Waren & Dienstleistungen -0.57%
Finanzindustrie +0.11%
Pharma +0.74%
Technologie -0.31%
Telekommunikation +0.41%